New data on Lenvima + Keytruda versus sunitinib from Phase III KEYNOTE 581 study in first-line treatment for patients with advanced renal cell carcinoma. Eisai + Merck Inc.
Eisai Co., Ltd. and Merck & Co., Inc., announced new investigational data from the pivotal Phase III CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor plus Keytruda, the anti-PD-1 therapy from Merck Inc., and Lenvima plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC).